Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Align Technology Inc. pages available for free this week:
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Present Value of Free Cash Flow to Equity (FCFE)
- Selected Financial Data since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Book Value (P/BV) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Align Technology Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
The financial data reveals notable fluctuations in profitability and efficiency ratios over the five-year period from 2018 to 2022. These changes reflect shifts in the company's operational performance and returns to shareholders and assets.
- Gross Profit Margin
- The gross profit margin maintained relatively high levels throughout the period, ranging from 70.52% to 74.26%. It peaked in 2021 at 74.26% but declined to 70.52% in 2022, indicating a slight contraction in cost efficiency or pricing power towards the end of the period.
- Operating Profit Margin
- This margin exhibited considerable volatility. After a moderate decline from 23.73% in 2018 to 15.66% in 2020, it rebounded to 24.7% in 2021, suggesting improved operational control or cost management. However, it fell again to 17.21% in 2022, signaling potential challenges in managing operating expenses or lower operating income.
- Net Profit Margin
- The net profit margin shows an unusual spike in 2020 at 71.84%, a figure that markedly deviates from its otherwise stable range between approximately 9.68% and 20.35%. This anomaly suggests the occurrence of a one-time event or accounting adjustment that significantly increased net income relative to revenue during that year. Excluding this outlier, the trend is downward in recent years, with profitability declining to 9.68% in 2022.
- Return on Equity (ROE)
- ROE follows a pattern of fluctuation consistent with net profit margins. It reached its highest level in 2020 at 54.92%, further supporting the indication of an exceptional gain in that year. Subsequently, ROE declined sharply to 21.31% in 2021 and more than halved again to 10.04% in 2022, highlighting a diminishing ability to generate shareholder returns.
- Return on Assets (ROA)
- ROA trends closely mirror those of ROE, albeit at lower levels due to the inclusion of total assets in the denominator. After increasing substantially to 36.77% in 2020, ROA declined markedly to 12.99% in 2021 and further to 6.08% in 2022, indicating a reduction in the efficiency of asset utilization over time.
In summary, the data suggests a period of strong profitability and efficiency peaking around 2020, likely influenced by extraordinary factors. However, the subsequent years reflect a decline in profit margins and returns, raising concerns about sustaining previous performance levels. The drop in gross and operating margins coupled with declining ROE and ROA in 2022 points to increased operational challenges and lower overall profitability.
Return on Sales
Return on Investment
Gross Profit Margin
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Gross profit | ||||||
Net revenues | ||||||
Profitability Ratio | ||||||
Gross profit margin1 | ||||||
Benchmarks | ||||||
Gross Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Gross profit margin = 100 × Gross profit ÷ Net revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends over the five-year period ending in 2022. Net revenues exhibited consistent growth from 2018 through 2021, rising from approximately $1.97 billion to nearly $3.95 billion. However, in 2022, net revenues decreased to about $3.73 billion, indicating a decline after several years of expansion.
Gross profit also followed a generally upward trajectory until 2021, increasing from around $1.45 billion in 2018 to nearly $2.94 billion in 2021. Similar to net revenues, gross profit declined in 2022 to approximately $2.63 billion. This suggests that despite growth in earlier years, both sales volume and cost management faced challenges in the latest period.
The gross profit margin percentage highlights some fluctuations in profitability. Starting at 73.63% in 2018, the margin gradually declined to 71.33% in 2020, before improving to a peak of 74.26% in 2021. In 2022, the gross profit margin contracted again to 70.52%, the lowest observed over the period. This variation points to possible changes in cost structures, pricing strategies, or product mix impacting overall margin performance.
- Net Revenues
- Strong growth from 2018 to 2021, followed by a noticeable reduction in 2022.
- Gross Profit
- Increased steadily until 2021, then fell alongside revenues in 2022.
- Gross Profit Margin
- Experienced minor declines early on, peaked in 2021, and decreased to the lowest level in 2022, indicating margin pressure.
Overall, the data suggests a positive growth trend up to 2021, with a reversal in both sales and profitability metrics in 2022. The reduction in gross profit margin during the last year further indicates increased cost pressures or competitive factors affecting profitability.
Operating Profit Margin
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Income from operations | ||||||
Net revenues | ||||||
Profitability Ratio | ||||||
Operating profit margin1 | ||||||
Benchmarks | ||||||
Operating Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Operating Profit Margin, Sector | ||||||
Health Care Equipment & Services | ||||||
Operating Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Operating profit margin = 100 × Income from operations ÷ Net revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
The analysis of the financial data reveals several notable trends over the five-year period.
- Net Revenues
- Net revenues show a consistent increase from 2018 to 2021, rising from approximately 1.97 billion USD in 2018 to nearly 3.95 billion USD in 2021. However, there is a slight decline in 2022, with revenues decreasing to about 3.73 billion USD. This suggests strong growth momentum over the first four years followed by a mild revenue contraction in the last year.
- Income from Operations
- Income from operations remained relatively stable from 2018 through 2020, with a slight dip in 2020 to approximately 387 million USD from over 542 million USD in 2019. There is a significant recovery and increase in 2021, with income from operations reaching nearly 976 million USD, which is the highest in the dataset. However, this figure decreases substantially in 2022 to about 643 million USD, indicating volatility in operating income during the latter part of the period.
- Operating Profit Margin
- The operating profit margin follows a somewhat fluctuating pattern, starting at 23.73% in 2018 and slightly decreasing to 22.54% in 2019. It declines further to 15.66% in 2020, indicating a reduction in operational efficiency during that year. In 2021, the margin recovers significantly to 24.7%, the highest in the period, suggesting improved cost management or favorable operating conditions. In 2022, the margin declines again to 17.21%, reflecting a decrease in profitability relative to revenue.
Overall, the period from 2018 to 2022 is characterized by substantial revenue growth and notable fluctuations in operating income and margin. The data indicates a challenging year in 2020 followed by a peak in operational performance in 2021. The slight downturn in both revenues and operating profit margin in 2022 suggests emerging headwinds affecting profitability. Monitoring the causes of these fluctuations would be essential for understanding the underlying business dynamics.
Net Profit Margin
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Net revenues | ||||||
Profitability Ratio | ||||||
Net profit margin1 | ||||||
Benchmarks | ||||||
Net Profit Margin, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
Net Profit Margin, Sector | ||||||
Health Care Equipment & Services | ||||||
Net Profit Margin, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
Net profit margin = 100 × Net income ÷ Net revenues
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income
- The net income demonstrates a fluctuating trend over the five-year period. Starting at approximately 400 million USD in 2018, it increased moderately to around 443 million USD in 2019. A significant spike is observed in 2020, peaking at nearly 1.78 billion USD. However, this peak was followed by a decline in the subsequent years, with net income reducing to roughly 772 million USD in 2021 and further dropping to approximately 362 million USD in 2022.
- Net Revenues
- Net revenues show an overall upward trajectory from 2018 through 2021. Beginning at about 1.97 billion USD in 2018, revenues steadily increased to approximately 2.41 billion USD in 2019 and 2.47 billion USD in 2020. A sharp increase took place in 2021, reaching close to 3.95 billion USD. However, a slight decline occurred in 2022, with revenues decreasing to around 3.73 billion USD.
- Net Profit Margin
- The net profit margin exhibits notable volatility during the analyzed period. Starting at 20.35% in 2018, it slightly declined to 18.4% in 2019. Subsequently, it experienced a dramatic increase in 2020, reaching 71.84%. This extraordinary peak aligns with the surge seen in net income that year. Afterwards, the margin contracted significantly in 2021 to 19.53% and further declined to 9.68% in 2022, indicating reduced profitability relative to revenues in the most recent year.
- Summary
- The data reveals a pattern of substantial variability in profitability and net income, with 2020 standing out as an exceptional year marked by a considerable spike in both net income and profit margin. Despite increasing revenues over most years, the sharp downturn in net income and profit margin from 2021 to 2022 suggests challenges in maintaining profitability. This divergence between revenue growth and profitability metrics in the latest periods may warrant further investigation into cost structures, market conditions, or other operational factors influencing financial performance.
Return on Equity (ROE)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Stockholders’ equity | ||||||
Profitability Ratio | ||||||
ROE1 | ||||||
Benchmarks | ||||||
ROE, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
ROE, Sector | ||||||
Health Care Equipment & Services | ||||||
ROE, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
ROE = 100 × Net income ÷ Stockholders’ equity
= 100 × ÷ =
2 Click competitor name to see calculations.
- Net Income
- Net income demonstrated significant volatility over the analyzed periods. After a moderate increase from 400,235 thousand USD in 2018 to 442,776 thousand USD in 2019, the figure surged dramatically to 1,775,888 thousand USD in 2020. However, this peak was followed by a sharp decline to 772,020 thousand USD in 2021 and a further decrease to 361,573 thousand USD in 2022. The data indicates a strong performance in 2020 that was not sustained in subsequent years.
- Stockholders’ Equity
- Stockholders’ equity increased steadily from 1,252,891 thousand USD in 2018 to 1,346,169 thousand USD in 2019. This was followed by a substantial rise in 2020, reaching 3,233,865 thousand USD. The upward trend continued through 2021 with equity reaching 3,622,714 thousand USD, then stabilizing in 2022 at 3,601,358 thousand USD. The large increase in 2020 and continued growth indicates strong capital accumulation during these years.
- Return on Equity (ROE)
- ROE exhibited a strong performance in 2018 and 2019, with values around 32%. This measure peaked at 54.92% in 2020, aligning with the surge in net income during the same year. However, ROE dropped significantly in 2021 to 21.31% and further declined to 10.04% in 2022, reflecting lower profitability relative to equity. This downward trend suggests reduced efficiency in generating earnings from shareholders’ equity in the latter years.
- Overall Analysis
- There is a clear pattern of peak financial performance in 2020, characterized by substantial increases in net income, stockholders’ equity, and ROE. Post-2020, the company experienced a marked decline in profitability as evidenced by decreased net income and ROE, despite stockholders’ equity remaining relatively high and stable. This suggests that while the company maintained its capital base, its ability to generate earnings from this base weakened. The data highlights the need for investigating the factors driving the 2020 peak and the causes of the subsequent decline in profitability metrics.
Return on Assets (ROA)
Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | ||
---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | ||||||
Net income | ||||||
Total assets | ||||||
Profitability Ratio | ||||||
ROA1 | ||||||
Benchmarks | ||||||
ROA, Competitors2 | ||||||
Abbott Laboratories | ||||||
CVS Health Corp. | ||||||
Elevance Health Inc. | ||||||
Intuitive Surgical Inc. | ||||||
Medtronic PLC | ||||||
UnitedHealth Group Inc. | ||||||
ROA, Sector | ||||||
Health Care Equipment & Services | ||||||
ROA, Industry | ||||||
Health Care |
Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).
1 2022 Calculation
ROA = 100 × Net income ÷ Total assets
= 100 × ÷ =
2 Click competitor name to see calculations.
The financial data exhibits distinct trends in profitability, asset growth, and return on assets over the five-year period.
- Net Income
- Net income demonstrated significant fluctuations. Starting at 400,235 thousand US dollars in 2018, it increased moderately to 442,776 thousand in 2019, followed by a substantial surge to 1,775,888 thousand in 2020. However, this peak was not sustained, as net income declined sharply to 772,020 thousand in 2021 and further reduced to 361,573 thousand in 2022. This pattern indicates a high level of volatility in earnings performance, with a pronounced spike in 2020 being an exceptional year.
- Total Assets
- Total assets showed consistent growth throughout the period. Beginning at 2,052,458 thousand US dollars in 2018, assets increased steadily each year reaching 2,500,702 thousand in 2019, followed by a significant expansion to 4,829,683 thousand in 2020. Growth continued albeit at a slower pace with total assets rising to 5,942,110 thousand in 2021 and 5,947,947 thousand in 2022. This sustained asset growth reflects the company's expanding resource base and potential for operational scale.
- Return on Assets (ROA)
- Return on assets exhibited considerable variability in response to net income fluctuations and asset growth. ROA started at 19.5% in 2018 and slightly decreased to 17.71% in 2019. In 2020, ROA nearly doubled to 36.77%, aligning with the substantial increase in net income relative to asset base. Following this peak, ROA declined sharply to 12.99% in 2021 and further down to 6.08% in 2022. The decline in ROA despite asset growth suggests reduced efficiency in asset utilization or lower profitability margins during the latter years.
Overall, the data indicates that while the asset base continued to grow steadily, profitability experienced notable volatility, particularly with an exceptional year in 2020, followed by a marked slowing down in earnings growth. The decreasing return on assets in the most recent years highlights challenges in maintaining profitability relative to the growing asset base.